MetaCap

Alnylam Pharmaceuticals (ALNY) vs Dr. Reddy's Laboratories (RDY)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Dr. Reddy's Laboratories (RDY) has outperformed Alnylam Pharmaceuticals (ALNY) over the past year, gaining 7.0% versus a loss of 67.0%. Over five years, RDY leads with a +18.2% price change compared with -23.7% for ALNY. Alnylam Pharmaceuticals is the larger company by market cap ($19.26 billion vs $12.41 billion), about 1.6 times the size.

On valuation, Alnylam Pharmaceuticals trades at a lower forward P/E (14.5x vs 22.5x for Dr. Reddy's Laboratories). Dr. Reddy's Laboratories pays a dividend yielding 53.73%, while Alnylam Pharmaceuticals does not currently pay one. Dr. Reddy's Laboratories converts more of its revenue into profit, with a net margin of 17.4% versus 8.4%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

ALNY-67.04%RDY+7.05%
+14%-28%-71%
Nov 21, 20251 yearNov 20, 2026
ALNY-20.54%RDY+19.43%
+176%+68%-40%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

ALNY versus RDY key metrics
MetricALNYRDY
Share price$143.82$14.89
Market cap$19.26B$12.41B
1-day change-2.71%+0.40%
YTD return-63.83%+6.05%
1-year return-67.04%+7.05%
5-year return-23.72%+18.19%
P/E ratio (TTM)7.2641.36
Forward P/E14.5122.47
EPS (TTM)$19.80$0.36
Dividend yield0.00%53.73%
Annual dividend$0.00$8.00
Revenue (latest FY)$3.71B$3.81B
Revenue growth (YoY)+65.19%+13.76%
Net income (latest FY)$313.75M$663.00M
Gross margin81.77%58.51%
Operating margin13.51%22.09%
Net margin8.45%17.40%
52-week high$479.79$15.67
52-week low$143.40$11.36
Distance from 52-week high-70.02%-4.98%
Analyst consensusbuybuy
Avg. price target upside+101.10%+0.20%
Average volume2.09M2.85M
Shares outstanding133.94M833.66M
Employees2,50027,527
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • RDY has outperformed ALNY by 74.1 percentage points over the past year.
  • Dr. Reddy's Laboratories trades at a higher earnings multiple (41.4x vs 7.3x trailing P/E).
  • Dr. Reddy's Laboratories offers a meaningfully higher dividend yield (53.73% vs 0.00%).
  • Dr. Reddy's Laboratories is more profitable, keeping 17.4 cents of every revenue dollar as net income versus 8.4 cents for Alnylam Pharmaceuticals.
  • Alnylam Pharmaceuticals grew revenue faster in its latest fiscal year (+65.19% vs +13.76%).

About Alnylam Pharmaceuticals

ALNY stock →

Alnylam Pharmaceuticals, Inc. discovers, develops, manufactures, and commercializes therapeutics based on ribonucleic acid interference in the United States, Europe, and internationally.

Health Care · Biotechnology: Pharmaceutical Preparations · 2,500 employees

About Dr. Reddy's Laboratories

RDY stock →

Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company North America, Europe, India, Russia, and internationally.

Health Care · Biotechnology: Pharmaceutical Preparations · 27,527 employees

ALNY vs RDY FAQ

Which is bigger, Alnylam Pharmaceuticals or Dr. Reddy's Laboratories?

Alnylam Pharmaceuticals (ALNY) is larger, with a market capitalization of $19.26B compared with $12.41B for Dr. Reddy's Laboratories (RDY).

Which stock has performed better over the past year, ALNY or RDY?

RDY returned +7.05% over the past 12 months, compared with -67.04% for ALNY (price return, excluding dividends). Past performance does not predict future results.

Which has the lower P/E ratio, ALNY or RDY?

ALNY has the lower trailing P/E at 7.3, versus 41.4 for RDY. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.

Which pays a higher dividend, Alnylam Pharmaceuticals or Dr. Reddy's Laboratories?

Dr. Reddy's Laboratories pays a dividend yielding 53.73%, while Alnylam Pharmaceuticals does not currently pay a regular dividend.

Are Alnylam Pharmaceuticals and Dr. Reddy's Laboratories in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons